CD200 and B-cell chronic lymphocytic leukemia: Very recently, the first-in-human study investigating the therapeutic use of the recombinant humanized monoclonal anti-CD200 antibody samalizumab in 23 patients with advanced CLL and 3 patients with MM was published (phase 1 study NCT00648738) (80).